世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

免疫測定法の市場規模、シェア、動向分析レポート:製品別(試薬・キット、分析装置・機器)、技術別(RIA、ELISA)、用途別、検体別、最終用途別、地域別、セグメント別予測、2024年~2030年


Immunoassay Market Size, Share & Trends Analysis Report By Product (Reagent & Kits, Analyzers/Instruments), By Technology (RIA, ELISA), By Application, By Specimen, By End-use, By Region, And Segment Forecasts, 2024 - 2030

免疫測定市場の成長と動向 Grand View Research社の最新レポートによると、世界のイムノアッセイ市場規模は2030年までに344億7000万米ドルに達すると予測されている。2024年から2030年までのCAGRは3.60%で市場... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月29日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
180 英語

1~3営業日


 

サマリー

免疫測定市場の成長と動向

Grand View Research社の最新レポートによると、世界のイムノアッセイ市場規模は2030年までに344億7000万米ドルに達すると予測されている。2024年から2030年までのCAGRは3.60%で市場拡大が見込まれている。PoC迅速検査や自動免疫測定分析装置の導入が市場成長を後押ししている。また、慢性疾患や感染症の増加が高い市場成長につながっている。

米国癌協会によると、2020年の癌患者/生存者数は推定1,690万人である。米国国立がん研究所2019年データによると、米国では約180万人のがん患者が診断された。米国がん協会によると、2019年に米国でがんが原因で約606,880人が死亡した。このように、がんと診断される症例数の増加がイムノアッセイの需要を促進している。これは、今後数年間の市場成長を押し上げると予想される。

さらに、感染症や予防対策に関する意識の高まりが、迅速診断検査製品への高い需要につながり、売上を伸ばしている。WHOによるWorld malaria report 2018の調査によると、メーカーは2017年にラテラルフローアッセイの売上高を2億7,600万と報告している。また、2017年にサハラ以南のアフリカで約75.0%のマラリア症例がラテラルフローアッセイを用いて診断されたことも報告されている。

いくつかのスマートフォンベースの機器や関連ツールが次世代のポイントオブケア診断や検査機器として登場し、市場の成長を後押ししている。例えば、自律型キャピラリーマイクロ流体チップと組み合わせたスマートフォンアプリケーションは、心筋梗塞における心筋トロポニンIの迅速検査に使用されている。このプラットフォームは、資源が限られた環境でも容易に使用でき、12分以内に検査結果を得ることができる。このように、新技術の進歩は予測期間中、市場をさらに牽引すると予想される。

米国におけるAptioオートメーション付きAtellica免疫測定ソリューションの最初の導入は、2018年4月にSiemens Healthcare GmbHによって発表された。この製品の目的は、米国で先進技術製品を普及させるために設計された。2020年12月、Danaherの事業であるBeckman Coulterは、COVID-19抗原検出のための最初の高品質だけでなくスループットアッセイを発表し、正式名称はAccess SARS-CoV-2 Antigen assayとなった。2018年7月、Cygnus TechnologiesとGyros Protein Technologiesは、バイオ治療毒素を同定するイムノアッセイを製造するために提携した。両社の戦略的提携は、主にバイオ分析ソリューションの提供とバイオ治療薬製造の効率化に重点を置く。

イムノアッセイ市場レポートハイライト

- 酵素免疫測定法(EIA)セグメントは、感染症や慢性疾患、食物アレルギー、薬物乱用などの用途で繰り返し使用されていることから、2023年には63.39%の最大市場シェアを占めた。

- 試薬・キット部門は、2023年に66.16%の最大シェアを占めた。大きな市場シェアは、感染症や自己免疫疾患の有病率の上昇に起因する免疫測定試薬と診断キットの需要増に起因している。

- 用途別では、感染症検査分野が2023年に36.39%の最大市場シェアを占め、予測期間中に最も速いCAGRで成長すると予測されている。

- 血液検体セグメントは、2023年に43.11%の最大シェアを占めた。これは、疾病の発生が増加し、さまざまな血液検査手順の需要が高まり、セグメントの成長を支えているためである。

- 最終用途に基づくと、病院セグメントは2023年に32.94%の収益シェアで市場を支配した。病院と診療所は、病状の診断と治療のためのプライマリケアの場である。

- 2023年には北米が40.60%の収益シェアで最も高い収益を上げた。慢性疾患に関連する診断への需要の高まりと、技術的に高度な診断技術の利用可能性の増加が、予測期間中の市場成長を促進すると予想される。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Rising incidence of chronic and infectious diseases
3.3.2. Increasing demand for point-of-care diagnostics
3.3.3. Growing demand for portable and automated immunoassays
3.4. Market Drivers
3.4.1. Lower detection limit
3.4.2. Limitations associated with immunoassay techniques
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Immunoassay market: Product Movement Analysis
4.2. Reagents & Kits
4.2.1. Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.2. ELISA Reagents & Kits
4.2.2.1. ELISA Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.3. Rapid Test Reagents & Kits
4.2.3.1. Rapid Test Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.4. ELISPOT Reagents & Kits
4.2.4.1. ELISPOT Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.5. Western Blot Reagents & Kits
4.2.5.1. Western Blot Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.6. Other Reagents & Kits
4.2.6.1. Other Reagents & Kits Market, 2018 - 2030 (USD Million)
4.3. Analyzers/Instruments
4.3.1. Analyzers/Instruments Market, 2018 - 2030 (USD Million)
4.3.2. Open Ended Systems
4.3.2.1. Open Ended Systems & Kits Market, 2018 - 2030 (USD Million)
4.3.3. Close Ended Systems
4.3.3.1. Close Ended Systems Reagents & Kits Market, 2018 - 2030 (USD Million)
4.4. Software & Services
4.4.1. Software & Services Market, 2018 - 2030 (USD Million)
Chapter 5. Specimen Business Analysis
5.1. Immunoassay Market: Specimen Movement Analysis
5.2. Blood
5.2.1. Blood Market, 2018 - 2030 (USD Million)
5.3. Saliva
5.3.1. Saliva Market, 2018 - 2030 (USD Million)
5.4. Urine
5.4.1. Urine Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Technology Business Analysis
6.1. Immunoassay Market: Technology Movement Analysis
6.2. Radioimmunoassay
6.2.1. Radioimmunoassay Market, 2018 - 2030 (USD Million)
6.3. Enzyme Immunoassays Rapid Test
6.3.1. Enzyme Immunoassays Rapid Test Market, 2018 - 2030 (USD Million)
6.3.2. Chemiluminescence Immunoassays
6.3.2.1. Chemilluminescence Immunoassays Market, 2018 - 2030 (USD Million)
6.3.3. Fluroscence Immunoassays
6.3.3.1. Fluroscence Immunoassays Market, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. End-use Business Analysis
7.1. Immunoassay Market: Distribution Channel Movement Analysis
7.2. Hospitals
7.2.1. Hospitals Market, 2018 - 2030 (USD Million)
7.3. Homecare
7.3.1. Homecare Market, 2018 - 2030 (USD Million)
7.4. Specialty Clinics
7.4.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. End-use Business Analysis
8.1. Immunoassay Market: Distribution Channel Movement Analysis
8.2. Hospitals
8.2.1. Hospitals Market, 2018 - 2030 (USD Million)
8.3. Blood Banks
8.3.1. Blood Banks Market, 2018 - 2030 (USD Million)
8.4. Clinical Laboratories
8.4.1. Clinical Laboratories Market, 2018 - 2030 (USD Million)
8.5. Pharmaceutical and Biotech Companies
8.5.1. Pharmaceutical and Biotech Companies Market, 2018 - 2030 (USD Million)
8.6. Academic Research Centers
8.6.1. Academic Research Centers Market, 2018 - 2030 (USD Million)
8.7. Others
8.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 9. Regional Business Analysis
9.1. Immunoassay Market Share By Region, 2023 & 2030
9.2. North America
9.2.1. North America Immunoassay market, 2018 - 2030 (USD Million)
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Competitive Scenario
9.2.2.4. Regulatory Framework
9.2.2.5. Reimbursement Scenario
9.2.2.6. U.S. Immunoassay market, 2018 - 2030 (USD MILLION)
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. Regulatory Framework
9.2.3.5. Reimbursement Scenario
9.2.3.6. Canada Immunoassay market, 2018 - 2030 (USD Million)
9.3. Europe
9.3.1. Europe Immunoassay market, 2018 - 2030 (USD Million)
9.3.2. Germany
9.3.2.1. Key Country Dynamics
9.3.2.2. Target Disease Prevalence
9.3.2.3. Competitive Scenario
9.3.2.4. Regulatory Framework
9.3.2.5. Reimbursement Scenario
9.3.2.6. Germany Immunoassay market, 2018 - 2030 (USD Million)
9.3.3. UK
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Competitive Scenario
9.3.3.4. Regulatory Framework
9.3.3.5. Reimbursement Scenario
9.3.3.6. UK Immunoassay market, 2018 - 2030 (USD Million)
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Competitive Scenario
9.3.4.4. Regulatory Framework
9.3.4.5. Reimbursement Scenario
9.3.4.6. France Immunoassay market, 2018 - 2030 (USD Million)
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Competitive Scenario
9.3.5.4. Regulatory Framework
9.3.5.5. Reimbursement Scenario
9.3.5.6. Italy Immunoassay market, 2018 - 2030 (USD Million)
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Competitive Scenario
9.3.6.4. Regulatory Framework
9.3.6.5. Reimbursement Scenario
9.3.6.6. Spain Immunoassay market, 2018 - 2030 (USD Million)
9.3.7. Denmark
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Competitive Scenario
9.3.7.4. Regulatory Framework
9.3.7.5. Reimbursement Scenario
9.3.7.6. Denmark Immunoassay market, 2018 - 2030 (USD Million)
9.3.8. Sweden
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Competitive Scenario
9.3.8.4. Regulatory Framework
9.3.8.5. Reimbursement Scenario
9.3.8.6. Sweden Immunoassay market, 2018 - 2030 (USD Million)
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Competitive Scenario
9.3.9.4. Regulatory Framework
9.3.9.5. Reimbursement Scenario
9.3.9.6. Norway Immunoassay market, 2018 - 2030 (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Immunoassay market, 2018 - 2030 (USD Million)
9.4.2. Japan
9.4.2.1. Key Country Dynamics
9.4.2.2. Target Disease Prevalence
9.4.2.3. Competitive Scenario
9.4.2.4. Regulatory Framework
9.4.2.5. Reimbursement Scenario
9.4.2.6. Japan Immunoassay market, 2018 - 2030 (USD Million)
9.4.3. China
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Competitive Scenario
9.4.3.4. Regulatory Framework
9.4.3.5. Reimbursement Scenario
9.4.3.6. China Immunoassay market, 2018 - 2030 (USD Million)
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Competitive Scenario
9.4.4.4. Regulatory Framework
9.4.4.5. Reimbursement Scenario
9.4.4.6. India Immunoassay market, 2018 - 2030 (USD Million)
9.4.5. South Korea
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Competitive Scenario
9.4.5.4. Regulatory Framework
9.4.5.5. Reimbursement Scenario
9.4.5.6. South Korea Immunoassay market, 2018 - 2030 (USD Million)
9.4.6. Australia
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Competitive Scenario
9.4.6.4. Regulatory Framework
9.4.6.5. Reimbursement Scenario
9.4.6.6. Australia Immunoassay market, 2018 - 2030 (USD Million)
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Competitive Scenario
9.4.7.4. Regulatory Framework
9.4.7.5. Reimbursement Scenario
9.4.7.6. Thailand Immunoassay market, 2018 - 2030 (USD Million)
9.5. Latin America
9.5.1. Latin America Immunoassay market, 2018 - 2030 (USD Million)
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Target Disease Prevalence
9.5.2.3. Competitive Scenario
9.5.2.4. Regulatory Framework
9.5.2.5. Reimbursement Scenario
9.5.2.6. Brazil Immunoassay market, 2018 - 2030 (USD Million)
9.5.3. Mexico
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Competitive Scenario
9.5.3.4. Regulatory Framework
9.5.3.5. Reimbursement Scenario
9.5.3.6. Mexico Immunoassay market, 2018 - 2030 (USD Million)
9.5.4. Argentina
9.5.4.1. Key Country Dynamics
9.5.4.2. Target Disease Prevalence
9.5.4.3. Competitive Scenario
9.5.4.4. Regulatory Framework
9.5.4.5. Reimbursement Scenario
9.5.4.6. Argentina Immunoassay market, 2018 - 2030 (USD Million)
9.6. MEA
9.6.1. MEA Immunoassay market, 2018 - 2030 (USD Million)
9.6.2. South Africa
9.6.2.1. Key Country Dynamics
9.6.2.2. Target Disease Prevalence
9.6.2.3. Competitive Scenario
9.6.2.4. Regulatory Framework
9.6.2.5. Reimbursement Scenario
9.6.2.6. South Africa Immunoassay market, 2018 - 2030 (USD Million)
9.6.3. Saudi Arabia
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Competitive Scenario
9.6.3.4. Regulatory Framework
9.6.3.5. Reimbursement Scenario
9.6.3.6. Saudi Arabia Immunoassay market, 2018 - 2030 (USD Million)
9.6.4. UAE
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Competitive Scenario
9.6.4.4. Regulatory Framework
9.6.4.5. Reimbursement Scenario
9.6.4.6. UAE Immunoassay market, 2018 - 2030 (USD Million)
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Competitive Scenario
9.6.5.4. Regulatory Framework
9.6.5.5. Reimbursement Scenario
9.6.5.6. Kuwait Immunoassay market, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Participant’s overview
10.2. Financial performance
10.3. Participant categorization
10.3.1. Market Leaders
10.3.2. Immunoassay market Share Analysis, 2023
10.3.3. Company Profiles
10.3.3.1. Siemens Healthineers
10.3.3.1.1. Company Overview
10.3.3.1.2. Financial Performance
10.3.3.1.3. Product Benchmarking
10.3.3.1.4. Strategic Initiatives
10.3.3.2. bioMérieux SA
10.3.3.2.1. Company Overview
10.3.3.2.2. Financial Performance
10.3.3.2.3. Product Benchmarking
10.3.3.2.4. Strategic Initiatives
10.3.3.3. Abbott Laboratories
10.3.3.3.1. Company Overview
10.3.3.3.2. Financial Performance
10.3.3.3.3. Product Benchmarking
10.3.3.3.4. Strategic Initiatives
10.3.3.4. Danaher Corporation (Beckman Coulter)
10.3.3.4.1. Company Overview
10.3.3.4.2. Financial Performance
10.3.3.4.3. Product Benchmarking
10.3.3.4.4. Strategic Initiatives
10.3.3.5. Quidel Corporation
10.3.3.5.1. Company Overview
10.3.3.5.2. Financial Performance
10.3.3.5.3. Product Benchmarking
10.3.3.5.4. Strategic Initiatives
10.3.3.6. Ortho Clinical Diagnostics
10.3.3.6.1. Company Overview
10.3.3.6.2. Financial Performance
10.3.3.6.3. Product Benchmarking
10.3.3.6.4. Sysmex Corporation
10.3.3.7. Bio-Rad Laboratories, Inc.
10.3.3.7.1. Company Overview
10.3.3.7.2. Financial Performance
10.3.3.7.3. Product Benchmarking
10.3.3.7.4. Strategic Initiatives
10.3.3.8. Becton, Dickinson, and Company
10.3.3.8.1. Company Overview
10.3.3.8.2. Financial Performance
10.3.3.8.3. Product Benchmarking
10.3.3.8.4. Strategic Initiatives
10.3.3.9. F. Hoffmann-La Roche AG
10.3.3.9.1. Company Overview
10.3.3.9.2. Financial Performance
10.3.3.9.3. Product Benchmarking
10.3.3.9.4. Strategic Initiatives
10.3.3.10. Thermo Fisher Scientific, Inc
10.3.3.10.1. Company Overview
10.3.3.10.2. Financial Performance
10.3.3.10.3. Product Benchmarking
10.3.3.10.4. Strategic Initiatives
10.3.3.11. Sysmex Corporation
10.3.3.11.1. Company Overview
10.3.3.11.2. Financial Performance
10.3.3.11.3. Product Benchmarking
10.3.3.11.4. Strategic Initiatives
10.3.4. Strategy Mapping
10.3.4.1. Expansion
10.3.4.2. Acquisition
10.3.4.3. Collaborations
10.3.4.4. Disease Type/Drug Class Launch
10.3.4.5. Partnerships
10.3.4.6. Others

 

ページTOPに戻る


 

Summary

Immunoassay Market Growth & Trends

The global immunoassay market size is expected to reach USD 34.47 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.60% from 2024 to 2030. The introduction of PoC rapid tests and automated immunoassay analyzers is boosting market growth. In addition, the rising number of chronic and infectious diseases is leading to high market growth.

According to the American Cancer Society, there were an estimated 16.9 million cancer patients/survivors in 2020. Around 1.8 million cancer cases were diagnosed in the U.S., according to the National Cancer Institute 2019 data. According to the American Cancer Society, nearly 606,880 deaths occurred due to cancer in the U.S. in 2019. Thus, the rise in the number of cancer cases being diagnosed is driving the demand for immunoassays. This is expected to boost the market growth in the coming years.

Furthermore, growing awareness regarding infectious diseases and preventive measures has led to a high demand for rapid diagnostic test products, thereby increasing sales. Based on a survey by the WHO on the World malaria report 2018, manufacturers reported sales of 276 million for lateral flow assays in 2017. It also reported that around 75.0% of malaria cases were diagnosed using lateral flow assays in sub-Saharan Africa in 2017.

Several smartphone-based devices and associated tools have emerged as next-generation point-of-care diagnostics or testing devices, thereby boosting the market growth. For instance, a smartphone application combined with the autonomous capillary microfluidic chip is used for the rapid testing of cardiac troponin I in myocardial infarction. This platform can be easily used in resource-limited settings, providing test results within 12 minutes. Thus, novel technological advancements are anticipated to further drive the market over the forecast period.

The first implementation of the Atellica immunoassay solutions with Aptio automation in the United States was announced by Siemens Healthcare GmbH in April 2018. The objective of this product was designed to promote advanced technological products in the U.S. In December 2020, Beckman Coulter, a Danaher business, introduced its first high-quality as well as throughput assay for the COVID-19 antigen detection, officially named Access SARS-CoV-2 Antigen assay. In July 2018, Cygnus Technologies and Gyros Protein Technologies collaborated to produce immunoassay to identify biotherapeutic toxins. The two companies' strategic alliance will primarily focus on offering bioanalytical solutions and increasing biotherapeutics manufacturing efficiencies.

Immunoassay Market Report Highlights

• The enzyme immunoassays (EIA) segment held the largest market share of 63.39% in 2023, owing to their repeated usage in the detection of infectious and chronic diseases, food allergies, and drug abuse, among other applications.

• The reagents and kits segment contributed to the largest share of 66.16% in 2023. A significant market share can be attributed to the increased demand for immunoassay reagents and diagnostic kits, owing to the rising prevalence of infectious and autoimmune diseases.

• Based on application, the infectious diseases testing segment held the largest market share of 36.39% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period.

• The blood specimen segment held the largest share of 43.11% in 2023 attributed to an increase in disease occurrence, which drives demand for different blood testing procedures, supporting segment growth.

• Based on end-use, the hospitals segment dominated the market in 2023 with a revenue share of 32.94%. Hospitals and clinics are primary care settings for the diagnosis and treatment of medical conditions.

• North America generated the highest revenue in 2023 with a 40.60% revenue share. The rise in demand for diagnostics related to chronic diseases and the increase in availability of technologically advanced diagnostic techniques are expected to propel market growth over the forecast period.



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Rising incidence of chronic and infectious diseases
3.3.2. Increasing demand for point-of-care diagnostics
3.3.3. Growing demand for portable and automated immunoassays
3.4. Market Drivers
3.4.1. Lower detection limit
3.4.2. Limitations associated with immunoassay techniques
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Immunoassay market: Product Movement Analysis
4.2. Reagents & Kits
4.2.1. Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.2. ELISA Reagents & Kits
4.2.2.1. ELISA Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.3. Rapid Test Reagents & Kits
4.2.3.1. Rapid Test Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.4. ELISPOT Reagents & Kits
4.2.4.1. ELISPOT Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.5. Western Blot Reagents & Kits
4.2.5.1. Western Blot Reagents & Kits Market, 2018 - 2030 (USD Million)
4.2.6. Other Reagents & Kits
4.2.6.1. Other Reagents & Kits Market, 2018 - 2030 (USD Million)
4.3. Analyzers/Instruments
4.3.1. Analyzers/Instruments Market, 2018 - 2030 (USD Million)
4.3.2. Open Ended Systems
4.3.2.1. Open Ended Systems & Kits Market, 2018 - 2030 (USD Million)
4.3.3. Close Ended Systems
4.3.3.1. Close Ended Systems Reagents & Kits Market, 2018 - 2030 (USD Million)
4.4. Software & Services
4.4.1. Software & Services Market, 2018 - 2030 (USD Million)
Chapter 5. Specimen Business Analysis
5.1. Immunoassay Market: Specimen Movement Analysis
5.2. Blood
5.2.1. Blood Market, 2018 - 2030 (USD Million)
5.3. Saliva
5.3.1. Saliva Market, 2018 - 2030 (USD Million)
5.4. Urine
5.4.1. Urine Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Technology Business Analysis
6.1. Immunoassay Market: Technology Movement Analysis
6.2. Radioimmunoassay
6.2.1. Radioimmunoassay Market, 2018 - 2030 (USD Million)
6.3. Enzyme Immunoassays Rapid Test
6.3.1. Enzyme Immunoassays Rapid Test Market, 2018 - 2030 (USD Million)
6.3.2. Chemiluminescence Immunoassays
6.3.2.1. Chemilluminescence Immunoassays Market, 2018 - 2030 (USD Million)
6.3.3. Fluroscence Immunoassays
6.3.3.1. Fluroscence Immunoassays Market, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. End-use Business Analysis
7.1. Immunoassay Market: Distribution Channel Movement Analysis
7.2. Hospitals
7.2.1. Hospitals Market, 2018 - 2030 (USD Million)
7.3. Homecare
7.3.1. Homecare Market, 2018 - 2030 (USD Million)
7.4. Specialty Clinics
7.4.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. End-use Business Analysis
8.1. Immunoassay Market: Distribution Channel Movement Analysis
8.2. Hospitals
8.2.1. Hospitals Market, 2018 - 2030 (USD Million)
8.3. Blood Banks
8.3.1. Blood Banks Market, 2018 - 2030 (USD Million)
8.4. Clinical Laboratories
8.4.1. Clinical Laboratories Market, 2018 - 2030 (USD Million)
8.5. Pharmaceutical and Biotech Companies
8.5.1. Pharmaceutical and Biotech Companies Market, 2018 - 2030 (USD Million)
8.6. Academic Research Centers
8.6.1. Academic Research Centers Market, 2018 - 2030 (USD Million)
8.7. Others
8.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 9. Regional Business Analysis
9.1. Immunoassay Market Share By Region, 2023 & 2030
9.2. North America
9.2.1. North America Immunoassay market, 2018 - 2030 (USD Million)
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Competitive Scenario
9.2.2.4. Regulatory Framework
9.2.2.5. Reimbursement Scenario
9.2.2.6. U.S. Immunoassay market, 2018 - 2030 (USD MILLION)
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. Regulatory Framework
9.2.3.5. Reimbursement Scenario
9.2.3.6. Canada Immunoassay market, 2018 - 2030 (USD Million)
9.3. Europe
9.3.1. Europe Immunoassay market, 2018 - 2030 (USD Million)
9.3.2. Germany
9.3.2.1. Key Country Dynamics
9.3.2.2. Target Disease Prevalence
9.3.2.3. Competitive Scenario
9.3.2.4. Regulatory Framework
9.3.2.5. Reimbursement Scenario
9.3.2.6. Germany Immunoassay market, 2018 - 2030 (USD Million)
9.3.3. UK
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Competitive Scenario
9.3.3.4. Regulatory Framework
9.3.3.5. Reimbursement Scenario
9.3.3.6. UK Immunoassay market, 2018 - 2030 (USD Million)
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Competitive Scenario
9.3.4.4. Regulatory Framework
9.3.4.5. Reimbursement Scenario
9.3.4.6. France Immunoassay market, 2018 - 2030 (USD Million)
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Competitive Scenario
9.3.5.4. Regulatory Framework
9.3.5.5. Reimbursement Scenario
9.3.5.6. Italy Immunoassay market, 2018 - 2030 (USD Million)
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Competitive Scenario
9.3.6.4. Regulatory Framework
9.3.6.5. Reimbursement Scenario
9.3.6.6. Spain Immunoassay market, 2018 - 2030 (USD Million)
9.3.7. Denmark
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Competitive Scenario
9.3.7.4. Regulatory Framework
9.3.7.5. Reimbursement Scenario
9.3.7.6. Denmark Immunoassay market, 2018 - 2030 (USD Million)
9.3.8. Sweden
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Competitive Scenario
9.3.8.4. Regulatory Framework
9.3.8.5. Reimbursement Scenario
9.3.8.6. Sweden Immunoassay market, 2018 - 2030 (USD Million)
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Competitive Scenario
9.3.9.4. Regulatory Framework
9.3.9.5. Reimbursement Scenario
9.3.9.6. Norway Immunoassay market, 2018 - 2030 (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Immunoassay market, 2018 - 2030 (USD Million)
9.4.2. Japan
9.4.2.1. Key Country Dynamics
9.4.2.2. Target Disease Prevalence
9.4.2.3. Competitive Scenario
9.4.2.4. Regulatory Framework
9.4.2.5. Reimbursement Scenario
9.4.2.6. Japan Immunoassay market, 2018 - 2030 (USD Million)
9.4.3. China
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Competitive Scenario
9.4.3.4. Regulatory Framework
9.4.3.5. Reimbursement Scenario
9.4.3.6. China Immunoassay market, 2018 - 2030 (USD Million)
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Competitive Scenario
9.4.4.4. Regulatory Framework
9.4.4.5. Reimbursement Scenario
9.4.4.6. India Immunoassay market, 2018 - 2030 (USD Million)
9.4.5. South Korea
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Competitive Scenario
9.4.5.4. Regulatory Framework
9.4.5.5. Reimbursement Scenario
9.4.5.6. South Korea Immunoassay market, 2018 - 2030 (USD Million)
9.4.6. Australia
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Competitive Scenario
9.4.6.4. Regulatory Framework
9.4.6.5. Reimbursement Scenario
9.4.6.6. Australia Immunoassay market, 2018 - 2030 (USD Million)
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Competitive Scenario
9.4.7.4. Regulatory Framework
9.4.7.5. Reimbursement Scenario
9.4.7.6. Thailand Immunoassay market, 2018 - 2030 (USD Million)
9.5. Latin America
9.5.1. Latin America Immunoassay market, 2018 - 2030 (USD Million)
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Target Disease Prevalence
9.5.2.3. Competitive Scenario
9.5.2.4. Regulatory Framework
9.5.2.5. Reimbursement Scenario
9.5.2.6. Brazil Immunoassay market, 2018 - 2030 (USD Million)
9.5.3. Mexico
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Competitive Scenario
9.5.3.4. Regulatory Framework
9.5.3.5. Reimbursement Scenario
9.5.3.6. Mexico Immunoassay market, 2018 - 2030 (USD Million)
9.5.4. Argentina
9.5.4.1. Key Country Dynamics
9.5.4.2. Target Disease Prevalence
9.5.4.3. Competitive Scenario
9.5.4.4. Regulatory Framework
9.5.4.5. Reimbursement Scenario
9.5.4.6. Argentina Immunoassay market, 2018 - 2030 (USD Million)
9.6. MEA
9.6.1. MEA Immunoassay market, 2018 - 2030 (USD Million)
9.6.2. South Africa
9.6.2.1. Key Country Dynamics
9.6.2.2. Target Disease Prevalence
9.6.2.3. Competitive Scenario
9.6.2.4. Regulatory Framework
9.6.2.5. Reimbursement Scenario
9.6.2.6. South Africa Immunoassay market, 2018 - 2030 (USD Million)
9.6.3. Saudi Arabia
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Competitive Scenario
9.6.3.4. Regulatory Framework
9.6.3.5. Reimbursement Scenario
9.6.3.6. Saudi Arabia Immunoassay market, 2018 - 2030 (USD Million)
9.6.4. UAE
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Competitive Scenario
9.6.4.4. Regulatory Framework
9.6.4.5. Reimbursement Scenario
9.6.4.6. UAE Immunoassay market, 2018 - 2030 (USD Million)
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Competitive Scenario
9.6.5.4. Regulatory Framework
9.6.5.5. Reimbursement Scenario
9.6.5.6. Kuwait Immunoassay market, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Participant’s overview
10.2. Financial performance
10.3. Participant categorization
10.3.1. Market Leaders
10.3.2. Immunoassay market Share Analysis, 2023
10.3.3. Company Profiles
10.3.3.1. Siemens Healthineers
10.3.3.1.1. Company Overview
10.3.3.1.2. Financial Performance
10.3.3.1.3. Product Benchmarking
10.3.3.1.4. Strategic Initiatives
10.3.3.2. bioMérieux SA
10.3.3.2.1. Company Overview
10.3.3.2.2. Financial Performance
10.3.3.2.3. Product Benchmarking
10.3.3.2.4. Strategic Initiatives
10.3.3.3. Abbott Laboratories
10.3.3.3.1. Company Overview
10.3.3.3.2. Financial Performance
10.3.3.3.3. Product Benchmarking
10.3.3.3.4. Strategic Initiatives
10.3.3.4. Danaher Corporation (Beckman Coulter)
10.3.3.4.1. Company Overview
10.3.3.4.2. Financial Performance
10.3.3.4.3. Product Benchmarking
10.3.3.4.4. Strategic Initiatives
10.3.3.5. Quidel Corporation
10.3.3.5.1. Company Overview
10.3.3.5.2. Financial Performance
10.3.3.5.3. Product Benchmarking
10.3.3.5.4. Strategic Initiatives
10.3.3.6. Ortho Clinical Diagnostics
10.3.3.6.1. Company Overview
10.3.3.6.2. Financial Performance
10.3.3.6.3. Product Benchmarking
10.3.3.6.4. Sysmex Corporation
10.3.3.7. Bio-Rad Laboratories, Inc.
10.3.3.7.1. Company Overview
10.3.3.7.2. Financial Performance
10.3.3.7.3. Product Benchmarking
10.3.3.7.4. Strategic Initiatives
10.3.3.8. Becton, Dickinson, and Company
10.3.3.8.1. Company Overview
10.3.3.8.2. Financial Performance
10.3.3.8.3. Product Benchmarking
10.3.3.8.4. Strategic Initiatives
10.3.3.9. F. Hoffmann-La Roche AG
10.3.3.9.1. Company Overview
10.3.3.9.2. Financial Performance
10.3.3.9.3. Product Benchmarking
10.3.3.9.4. Strategic Initiatives
10.3.3.10. Thermo Fisher Scientific, Inc
10.3.3.10.1. Company Overview
10.3.3.10.2. Financial Performance
10.3.3.10.3. Product Benchmarking
10.3.3.10.4. Strategic Initiatives
10.3.3.11. Sysmex Corporation
10.3.3.11.1. Company Overview
10.3.3.11.2. Financial Performance
10.3.3.11.3. Product Benchmarking
10.3.3.11.4. Strategic Initiatives
10.3.4. Strategy Mapping
10.3.4.1. Expansion
10.3.4.2. Acquisition
10.3.4.3. Collaborations
10.3.4.4. Disease Type/Drug Class Launch
10.3.4.5. Partnerships
10.3.4.6. Others

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート

Grand View Research社の医療機器分野での最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る